BiomX’s (PHGE) “Neutral” Rating Reaffirmed at HC Wainwright

BiomX (NYSEAMERICAN:PHGE)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a report released on Monday,Benzinga reports.

BiomX Stock Up 5.3%

PHGE traded up $0.36 during midday trading on Monday, reaching $7.17. The company had a trading volume of 73,134 shares, compared to its average volume of 1,351,705. BiomX has a 1 year low of $1.50 and a 1 year high of $14.71. The company has a market cap of $11.40 million, a P/E ratio of -0.28 and a beta of 1.68. The business has a 50-day moving average of $4.26 and a two-hundred day moving average of $6.56.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. On average, equities research analysts predict that BiomX will post -2.77 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC bought a new position in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent SEC filing. Hedge funds and other institutional investors own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.